Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 54 articles: HTML format

Single Articles

July 2021
1. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
   Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
   J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2021
2. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
   Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
   J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2021
3. CADHAM CJ, Cao P, Jayasekera J, Taylor KL, et al
   Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.
   J Natl Cancer Inst. 2021 Jan 23. pii: 6117330. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. LANDY R, Young CD, Skarzynski M, Cheung LC, et al
   Using Prediction-Models to Reduce Persistent Racial/Ethnic Disparities in Draft 2020 USPSTF Lung-Cancer Screening Guidelines.
   J Natl Cancer Inst. 2021 Jan 5. pii: 6064157. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. FEDEWA S, Silvestri GA
   Reducing Disparities in Lung Cancer Screening: It's Not so Black and White.
   J Natl Cancer Inst. 2021 Jan 5. pii: 6064154. doi: 10.1093.
   PubMed    
   
   
   December 2020
6. MITCHELL AP, Bach PB
   Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
   J Natl Cancer Inst. 2020;112:1177-1178.
   PubMed    
   
   
   November 2020
7. FEDEWA SA, Kazerooni EA, Studts JL, Smith R, et al
   State Variation in Low-Dose CT Scanning for Lung Cancer Screening in the United States.
   J Natl Cancer Inst. 2020 Nov 12. pii: 5970481. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2020
8. TAKVORIAN SU, Balogh E, Nass S, Valentin VL, et al
   Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action.
   J Natl Cancer Inst. 2020;112:663-670.
   PubMed     Abstract available
   
   
   March 2020
9. MORGAN RL, Karam SD, Bradley CJ
   Ethnic Disparities in PET/CT Utilization at Diagnosis of Non-Small Cell Lung Cancer.
   J Natl Cancer Inst. 2020 Mar 5. pii: 5781960. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2020
10. HAN SS, Chow E, Ten Haaf K, Toumazis I, et al
    Disparities of national lung cancer screening guidelines in the U.S. population.
    J Natl Cancer Inst. 2020 Feb 10. pii: 5732655. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2019
11. BRADLEY CJ, Eguchi M, Perraillon MC
    Factors associated with utilization of high cost agents for the treatment of metastatic non-small cell lung cancer.
    J Natl Cancer Inst. 2019 Nov 9. pii: 5618726. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2019
12. KATKI HA, Cheung LC, Landy R
    Basing eligibility for lung cancer screening on individualized risk calculators should save more lives, but life-expectancy matters.
    J Natl Cancer Inst. 2019 Sep 30. pii: 5578424. doi: 10.1093.
    PubMed    
    
    
    
13. TEN HAAF K, Bastani M, Cao P, Jeon J, et al
    A comparative modeling analysis of risk-based lung cancer screening strategies.
    J Natl Cancer Inst. 2019 Sep 30. pii: 5578423. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. CHOU YT, Farley JF, Stinchcombe TE, Proctor AE, et al
    The Association Between Medicare Low-income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5566498. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2019
15. CONFORTI F, Pala L, Bagnardi V, Viale G, et al
    Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2019 May 20. pii: 5491832. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. HUANG J, Weinstein SJ, Yu K, Mannisto S, et al
    A Prospective Study of Serum Vitamin E and 28-Year Risk of Lung Cancer.
    J Natl Cancer Inst. 2019 May 11. pii: 5488117. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2019
17. ROBBINS HA, Berg CD, Cheung LC, Chaturvedi AK, et al
    Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result.
    J Natl Cancer Inst. 2019 Apr 12. pii: 5445482. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2019
18. RAI A, Doria-Rose VP, Silvestri GA, Yabroff KR, et al
    Evaluating Lung Cancer Screening Uptake, Outcomes, and Costs in the United States: Challenges With Existing Data and Recommendations for Improvement.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304457. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. STRAM DO, Park SL, Haiman CA, Murphy SE, et al
    Racial/Ethnic Differences in Lung Cancer Incidence in the Multiethnic Cohort Study: An Update.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303811. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2018
20. KEHL KL, Lathan CS, Johnson BE, Schrag D, et al
    Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.
    J Natl Cancer Inst. 2018 Dec 20. pii: 5255663. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2018
21. YANG R, Li SW, Chen Z, Zhou X, et al
    Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
    J Natl Cancer Inst. 2018 Nov 13. pii: 5181309. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2018
22. HAHN EE, Gould MK
    Lung Cancer Screening and Smoking Cessation: Never Too Early or Too Late.
    J Natl Cancer Inst. 2018 May 16. pii: 4996950. doi: 10.1093.
    PubMed    
    
    
    
23. TINDLE HA, Stevenson Duncan M, Greevy RA, Vasan RS, et al
    Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study.
    J Natl Cancer Inst. 2018 May 16. pii: 4996947. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. RAFNAR T, Sigurjonsdottir GR, Stacey SN, Halldorsson G, et al
    Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin.
    J Natl Cancer Inst. 2018 May 14. pii: 4995938. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2018
25. NABI H, Provencher L, Diorio C
    RE: Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).
    J Natl Cancer Inst. 2018 Apr 20. pii: 4980806. doi: 10.1093.
    PubMed    
    
    
    
26. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available
    
    
    March 2018
27. SAMET JM
    Lung Cancer, Smoking, and Obesity: It's Complicated.
    J Natl Cancer Inst. 2018 Mar 6. pii: 4923351. doi: 10.1093.
    PubMed    
    
    
    
28. YU D, Zheng W, Johansson M, Lan Q, et al
    Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis.
    J Natl Cancer Inst. 2018 Mar 6. pii: 4923348. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. GILL RR, Yeap BY, Bueno R, Richards WG, et al
    Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
    J Natl Cancer Inst. 2018;110:258-264.
    PubMed     Abstract available
    
    
    February 2018
30. CEDRES S, Felip E, Cruz C, Martinez de Castro A, et al
    Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
    J Natl Cancer Inst. 2018 Feb 26. pii: 4911464. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2018
31. CHENG TD, Darke AK, Redman MW, Zirpoli GR, et al
    Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).
    J Natl Cancer Inst. 2018 Jan 13. pii: 4807490. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. LIN SH, Koong AC
    Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed    
    
    
    
33. SALEM A, Asselin MC, Reymen B, Jackson A, et al
    Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available
    
    
    
34. FANIDI A, Muller DC, Yuan JM, Stevens VL, et al
    Circulating Folate, Vitamin B6, and Methionine in Relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3).
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available
    
    
    
35. MLECNIK B, Van den Eynde M, Bindea G, Church SE, et al
    Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available
    
    
    
36. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available
    
    
    
37. HANLEY CJ, Mellone M, Ford K, Thirdborough SM, et al
    Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available
    
    
    December 2017
38. SONG MA, Benowitz NL, Berman M, Brasky TM, et al
    Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    
39. PIETRANTONIO F, Di Nicolantonio F, Schrock AB, Lee J, et al
    ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    November 2017
40. BACH PB, Saltz LB
    Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed    
    
    
    
41. GOLDSTEIN DA, Gordon N, Davidescu M, Leshno M, et al
    A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    October 2017
42. PAGE BJ, Bowman RV, Yang IA, Fong KM, et al
    RE: Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.
    J Natl Cancer Inst. 2017 Oct 16. doi: 10.1093.
    PubMed    
    
    
    September 2017
43. DENIS F, Lethrosne C, Pourel N, Molinier O, et al
    Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    
44. CHAIB I, Karachaliou N, Pilotto S, Codony Servat J, et al
    Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    July 2017
45. ZHOU B, Wang GZ, Wen ZS, Zhou YC, et al
    Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2017 Jul 17. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. ROBLES AI, Harris CC
    Lung Cancer Field Cancerization: Implications for Screening by Low-Dose Computed Tomography.
    J Natl Cancer Inst. 2017;109.
    PubMed    
    
    
    
47. 
    Shared Gene Expression Alterations in Nasal and Bronchial Epithelium for Lung Cancer Detection.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    June 2017
48. KAWAKAMI M, Mustachio LM, Rodriguez-Canales J, Mino B, et al
    Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    
49. LEE CK, Davies L, Wu YL, Mitsudomi T, et al
    Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available
    
    
    March 2017
50. XU W, Neckers L
    Editorial: A USE1ful Biomarker and Molecular Target in Lung Cancer?
    J Natl Cancer Inst. 2017;109:1-3.
    PubMed    
    
    
    
51. WELLER M, Roth P, Sahm F, Burghardt I, et al
    Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
    J Natl Cancer Inst. 2017;109:1-4.
    PubMed     Abstract available
    
    
    
52. KIM SJ, Hyeong Lee T, Hee Nam S, Kim JH, et al
    Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis.
    J Natl Cancer Inst. 2017;109:1-11.
    PubMed     Abstract available
    
    
    
53. CELIKTAS M, Tanaka I, Tripathi SC, Fahrmann JF, et al
    Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
    J Natl Cancer Inst. 2017;109:1-9.
    PubMed     Abstract available
    
    
    January 2017
54. SHUKLA S, Evans JR, Malik R, Feng FY, et al
    Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
    J Natl Cancer Inst. 2016;109.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: